Resnick Joshua 4

What Happened

• Joshua Resnick, a director of Sionna Therapeutics, was granted an award/option for 17,340 shares on 2026-06-17. The award is recorded as a derivative acquisition at $0.00 per share (no cash paid at grant). This is a grant of an option/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-17; filing date: 2026-06-18 (filed timely).
• Transaction type/code: Award/Grant (derivative) — 17,340 shares @ $0.00.
• Vesting: Option vests in full upon the earlier of June 17, 2027 or the date of Sionna’s next annual meeting, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• Notable footnote: Under an arrangement with RA Capital Management, L.P., Resnick holds the option for the benefit of certain RA Capital funds/accounts and must turn over any net cash or stock received on exercise to the Adviser to offset advisory fees; he disclaims beneficial ownership of the option and underlying common stock.

Context

• This is a derivative grant (an option/award) that vests in the future; it does not represent an immediate purchase or sale of common stock. Because the Reporting Person disclaims beneficial ownership under the adviser arrangement, the grant may primarily be an administrative award for services and may not reflect a direct investment signal by the director.